Innate immunity for better or worse govern the allograft response

Current Opinion in Organ Transplantation

Volumn 20, Issue 1, 2015, Pages 8-12

  Otterbein, Leo E ^a   Fan, Zhigang ^a   Koulmanda, Maria ^a   Thronley, Thomas ^a   Strom, Terry B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

damage associated molecular pattern molecules; tissue resident macrophages

Indexed keywords

ALPHA 1 ANTITRYPSIN; CORTICOSTEROID; CYTOKINE; ETHYLPYRUVIC ACID; GALECTIN; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; MITOCHONDRIAL DNA; MONOCLONAL ANTIBODY; PROTEIN S 100; PYRUVIC ACID DERIVATIVE; RASBURICASE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; URIC ACID;

ACUTE GRAFT REJECTION; ADAPTIVE IMMUNITY; ALLOGRAFT; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL HYPOXIA; CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; CRITICAL ILLNESS; DENDRITIC CELL; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; KIDNEY TRANSPLANTATION; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; REPERFUSION INJURY; REVASCULARIZATION; REVIEW; T LYMPHOCYTE; TRANSPLANTATION TOLERANCE; ANIMAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; ORGAN TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; ORGAN TRANSPLANTATION;

EID: 84921327714     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000152     Document Type: Review

References (21)

1. Bodonyi-Kovacs G, Putheti P, Marino M, et al. Gene expression profiling of the donor kidney at the time of transplantation predicts clinical outcomes 2 years after transplantation. Hum Immunol 2010; 71:451-455.
2. Avihingsanon Y, Ma N, Pavlakis M, et al. On the intraoperative molecular status of renal allografts after vascular reperfusion and clinical outcomes. J Am Soc Nephrol 2005; 16:1542-1548.
3. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-238.
4. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464:104-107.
5. Sun S, Sursal T, Adibnia Y, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One 2013; 8:e59989.
6. Nakahira K, Kyung SY, Rogers AJ, et al. Circulating mitochondrial DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med 2013; 10:e1001577; discussion e1001577.
7. la Sala A, Ferrari D, Di Virgilio F, et al. Alerting and tuning the immune response by extracellular nucleotides. J Leukoc Biol 2003; 73:339-343.
8. Maeda Y. Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses. Int J Hematol 2013; 98:293-299.
9. He Y, Zha J, Wang Y, et al. Tissue damage-Associated 'danger signals' influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer research 2013; 73:629-639.
10. Schwacha MG, Rani M, Zhang Q, et al. Mitochondrial damage-Associated molecular patterns activate gammadelta T-cells. Innate Immun 2014; 20:261-268.
11. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54:2060-2069.
12. Bennet W, Groth CG, Larsson R, et al. Isolated human islets trigger an instant blood mediated inflammatory reaction: implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Upsala J Med Sci 2000; 105:125-133.
13. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54:1755-1762.
14. Koulmanda M, Smith RN, Qipo A, et al. Prolonged survival of allogeneic islets in cynomolgus monkeys after short-Term anti-CD154-based therapy: nonimmunologic graft failure?, Am J Transplant 2006; 6:687-696.
15. Churg A, Dai J, Zay K, et al. Alpha-1-Antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest 2001; 81:1119-1131.
16. Jie Z, Cai Y, Yang W, et al. Protective effects of alpha 1-Antitrypsin on acute lung injury in rabbits induced by endotoxin. Chinese Med J 2003; 116:1678-1682.
17. Lewis EC, Shapiro L, Bowers OJ, et al. Alpha1-Antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci U S A 2005; 102:12153-12158.
18. Petrache I, Fijalkowska I, Zhen L, et al. A novel antiapoptotic role for alpha1-Antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006; 173:1222-1228.
19. Zhang B, Lu Y, Campbell-Thompson M, et al. Alpha1-Antitrypsin protects beta-cells from apoptosis. Diabetes 2007; 56:1316-1323.
20. Koulmanda M, Bhasin M, Fan Z, et al. Alpha 1-Antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival. Proc Natl Acad Sci U S A 2012; 109:15443-15448.
21. Thornley TB, Fang Z, Balasubramanian S, et al. Fragile TIM-4-expressing tissue resident macrophages are migratory and immunoregulatory. J Clin Invest 2014; 124:3443-3454.